Overview

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101

Status:
Recruiting

Trial end date:
2022-12-17

Target enrollment:

Participant gender:

Summary

This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intratumorally in participants with advanced solid tumors or lymphomas.

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

H3 Biomedicine Inc.

Treatments:

Interferons